Lipids and Renal Disease
نویسندگان
چکیده
منابع مشابه
Lipids and renal disease.
Chronic renal disease is accompanied by characteristic abnormalities of lipid metabolism, which appear as a consequence of nephrotic syndrome or renal insufficiency and are reflected in an altered apolipoprotein profile as well as elevated plasma lipid levels. Experimental and clinical studies have suggested a correlation between the progression of renal disease and dyslipidemia. High cholester...
متن کاملChronic Renal Failure and Its effects on Serum Lipids
Background: Metabolic disturbances and dyslipidemia are among the most important medical problems in human society. Their effects on the mortality of coronary heart disease (CHD) have lead to many investigations about them. Materials and Methods: An epidemiologic cross-sectional study was carried out on 10136 persons selected randomly in Tehran urban district 13 with a minimum age of 20 years ...
متن کاملSystemic and renal lipids in kidney disease development and progression.
Altered lipid metabolism characterizes proteinuria and chronic kidney diseases. While it is thought that dyslipidemia is a consequence of kidney disease, a large body of clinical and experimental studies support that altered lipid metabolism may contribute to the pathogenesis and progression of kidney disease. In fact, accumulation of renal lipids has been observed in several conditions of gene...
متن کاملTITLE : Systemic and renal lipids in kidney disease
Systemic and renal lipids in kidney disease development 1 and progression 2 3 AUTHORS: Patricia Wahl, Gloria Michelle Ducasa, Alessia Fornoni 4 INSTITUTION: Peggy and Harold Katz Family Drug Discovery Center and 5 Division of Nephrology and Hypertension 6 University of Miami Miller School of Medicine 7 8 RUNNING HEAD: Lipids in kidney disease 9 CORRESPONDENCE Alessia Fornoni MD PhD 10 Peggy and...
متن کاملLipids and Alzheimer's disease.
According to the World Health Organisation (WHO), the number of people suffering from Alzheimer's disease (AD) worldwide is around 18 million. The prevalence of AD doubles every five years between 65 and 85 years of age and it is estimated that due to the ageing population, 34 million people will suffer from AD by 2025. The WHO has also stated that if AD onset were delayed by 5 years, the numbe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Society of Nephrology
سال: 2006
ISSN: 1046-6673,1533-3450
DOI: 10.1681/asn.2005121320